#39 of 100 - Gina Life Diagnostics
Updated: Aug 18
Ovarian cancer is a lethal disease, as most patients are diagnosed at late stages. Millions of women world wide live in fear since currently there is no early detection test for ovarian cancer.
The American Cancer Society estimates that in 2020 about 21,750 women will receive a new diagnosis of ovarian cancer and approximately 13,940 women will die from the disease.
Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 78, while her lifetime chance of dying from ovarian cancer is about 1 in 108. The cancer mainly develops in older women with around half of all cases in patients aged 63 years or older.
Israeli startup Gina Life Diagnostics' mission is to bring a solution and hope to women at high risk for ovarian cancer, and to every woman who wants to take control over her health.
The company is developing a first of its kind, life saving smart diagnostic platform for the early detection of ovarian cancer.
The home-use detection test uses a proprietary biomarker fingerprint of untapped biofluid vaginal secretions. Combining a digital health approach and the use of untapped bio-fluid, Gina-Life will enable ovarian cancer early detection, and will make ovarian cancer a curable disease.
The company is at the proof-of-concept stage and is aiming to establish a personalized baseline for each woman so that detection of ovarian cancer can be spotted early and millions of lives can be saved.
Earlier this year, Gina Life was selected as a Finalist in the 2020 MassChallenge Israel Startup competition in the Healthcare /Life Sciences category.
CEO and Co-Founder Inbal Zafir-Lavie explained the motivation behind Gina Life Diagnostics:
"I see my job as a mission. As someone who lost a sister due to aggressive cancer, I decided to dedicate my professional life to developing technologies for early detection and cancer treatment.
I believe that the combination of quality people and quality science is the main motive of a successful pharma company. "